{"entity":{"id":"nct02773030","kind":"trial","name":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple","aka":[],"tldr":"A phase 1/2 trial of Iberdomide, Dexamethasone, Daratumumab in multiple myeloma, run by Celgene, active and no longer recruiting.","summary":"A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma is a phase 1/2 interventional study registered as NCT02773030 by Celgene, with 466 participants enrolled, started 2016-10-14 and due to reach its primary completion in 2024-05-09. Interventions recorded: CC-220, Dexamethasone, Daratumumab, Bortezomib, Carfilzomib. Conditions listed: Multiple Myeloma. Results were posted on ClinicalTrials.gov in 2026; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02773030","url":"https://clinicaltrials.gov/study/NCT02773030"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":["celmods","protac-degrader"],"targets":[],"drugs":["iberdomide","dexamethasone","daratumumab","bortezomib","carfilzomib"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02773030","phase":"1/2","setting":"Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma","sponsor":"Celgene","started":"2016-10-14","startedType":"actual","yearReported":2026,"enrolled":466,"enrolledBasis":"registry","outcomes":[{"endpoint":"Overall Response Rate (ORR) in Cohort D and Cohort H2","primary":true,"unit":"%","arms":[{"name":"Cohort D: Treatment 1","n":107,"value":26.2,"note":"95% CI 18.1 to 35.6; Figures from the ClinicalTrials.gov results section (first posted 2026-03-20), not from a publication"},{"name":"Cohort H2","n":5,"value":20,"note":"95% CI 0.5 to 71.6"}],"source":"https://clinicaltrials.gov/study/NCT02773030?tab=results"},{"endpoint":"Progression Free Survival","unit":"weeks","arms":[{"name":"Cohort A: Total","n":29,"value":12.29,"note":"range 0.1 to 395.0; Figures from the ClinicalTrials.gov results section (first posted 2026-03-20), not from a publication"},{"name":"Cohort B: Total","n":90,"value":14.71,"note":"range 0.1 to 247.0"},{"name":"Cohort D: Total","n":107,"value":12.14,"note":"range 0.1 to 150.1"},{"name":"Cohort E: Total","n":50,"value":20.71,"note":"range 2.1 to 269.1"},{"name":"Cohort F: Total","n":29,"value":15.14,"note":"range 0.1 to 258.1"},{"name":"Cohort G: Total","n":16,"value":48.57,"note":"range 4.1 to 246.3"},{"name":"Cohort H1","n":6,"value":26.14,"note":"range 5.3 to 213.1"},{"name":"Cohort H2","n":5,"value":22.14,"note":"range 8.3 to 46.7"},{"name":"Cohort I","n":41,"value":10.14,"note":"range 0.1 to 84.4"},{"name":"Cohort J: Total","n":18,"value":107,"note":"range 0.1 to 127.9"},{"name":"Cohort K","n":75,"value":57.14,"note":"range 0.1 to 81.3"}],"source":"https://clinicaltrials.gov/study/NCT02773030?tab=results"}]},"route":"/trials/nct02773030/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"celmods","kind":"technology","name":"Cereblon E3 ligase modulators (CELMoDs)","route":"/technologies/celmods/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"}],"drug":[{"id":"bortezomib","kind":"drug","name":"Bortezomib","route":"/drugs/bortezomib/"},{"id":"carfilzomib","kind":"drug","name":"Carfilzomib","route":"/drugs/carfilzomib/"},{"id":"daratumumab","kind":"drug","name":"Daratumumab","route":"/drugs/daratumumab/"},{"id":"dexamethasone","kind":"drug","name":"Dexamethasone","route":"/drugs/dexamethasone/"},{"id":"iberdomide","kind":"drug","name":"Iberdomide","route":"/drugs/iberdomide/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}]}}